乳房再建における訴訟とエビデンス：予防可能な合併症を理解するための新しいアプローチ

Breast reconstruction surgery can result in various complications, some of which lead to medical litigation or formal mediation. However, systematic comparison of these medicolegal cases with evidence-based preventive strategies from randomized controlled trials remains unexplored. This study employed a novel methodology comparing complications resulting in litigation/mediation with contemporary randomized controlled trial (RCT) evidence. A mixed-methods approach was utilized, combining systematic review of RCTs (PubMed, 2020-2024) following modified PRISMA guidelines with comprehensive analysis of medical litigation and mediation databases. Narrative synthesis compared complication patterns between medicolegal cases and preventive interventions evaluated in RCTs. Nineteen RCTs and seven medicolegal cases (5 litigations, 2 mediations) were analyzed. All cases involved complications for which preventive strategies have been evaluated in recent RCTs. In implant-based reconstruction, tissue necrosis leading to implant loss (3/5 cases, 60%) occurred despite RCT evidence showing 50% reduction with indocyanine green assessment and 37% reduction with prostaglandin E1 (34.3% to 21.6%, p < 0.001). Both autologous reconstruction cases developed abdominal hernias, contrasting with 1-3% rates using synthetic mesh versus 38% with biological materials (p < 0.001). None of these cases documented use of such strategies. Informed consent violations were identified in 86% of cases. Total awards (compensation plus consolation money) ranged from $0-34,509, granted in 86% (6/7) of cases. These findings suggest a gap between available evidence and documented clinical practice in complications severe enough to prompt litigation or formal mediation. The preventive strategies identified in this analysis-including indocyanine green perfusion assessment, prostaglandin E1 administration, and selective synthetic mesh reinforcement-represent potential opportunities for reducing catastrophic complications and medicolegal risk, though implementation must be individualized based on patient-specific factors, risks, costs, and resource availability.